TY - JOUR
T1 - Seroprevalence of hepatitis E virus in dromedary camels, Bedouins, Muslim Arabs and Jews in Israel, 2009–2017
AU - Bassal, R.
AU - Wax, M.
AU - Shirazi, R.
AU - Shohat, T.
AU - Cohen, D.
AU - David, D.
AU - Abu-Mouch, S.
AU - Abu-Ghanem, Y.
AU - Mendelson, E.
AU - Ben-Ari, Z.
AU - Mor, O.
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2019
Y1 - 2019
N2 - Hepatitis E virus (HEV) is an emerging cause of viral hepatitis worldwide. Recently, HEV-7 has been shown to infect camels and humans. We studied HEV seroprevalence in dromedary camels and among Bedouins, Arabs (Muslims, none-Bedouins) and Jews and assessed factors associated with anti-HEV seropositivity. Serum samples from dromedary camels (n = 86) were used to determine camel anti-HEV IgG and HEV RNA positivity. Human samples collected between 2009 and 2016 from >20 years old Bedouins (n = 305), non-Bedouin Arabs (n = 320) and Jews (n = 195), were randomly selected using an age-stratified sampling design. Human HEV IgG levels were determined using Wantai IgG ELISA assay. Of the samples obtained from camels, 68.6% were anti-HEV positive. Among the human populations, Bedouins and non-Bedouin Arabs had a significantly higher prevalence of HEV antibodies (21.6% and 15.0%, respectively) compared with the Jewish population (3.1%). Seropositivity increased significantly with age in all human populations, reaching 47.6% and 34.8% among ≥40 years old, in Bedouins and non-Bedouin Arabs, respectively. The high seropositivity in camels and in ≥40 years old Bedouins and non-Bedouin Arabs suggests that HEV is endemic in Israel. The low HEV seroprevalence in Jews could be attributed to higher socio-economic status.
AB - Hepatitis E virus (HEV) is an emerging cause of viral hepatitis worldwide. Recently, HEV-7 has been shown to infect camels and humans. We studied HEV seroprevalence in dromedary camels and among Bedouins, Arabs (Muslims, none-Bedouins) and Jews and assessed factors associated with anti-HEV seropositivity. Serum samples from dromedary camels (n = 86) were used to determine camel anti-HEV IgG and HEV RNA positivity. Human samples collected between 2009 and 2016 from >20 years old Bedouins (n = 305), non-Bedouin Arabs (n = 320) and Jews (n = 195), were randomly selected using an age-stratified sampling design. Human HEV IgG levels were determined using Wantai IgG ELISA assay. Of the samples obtained from camels, 68.6% were anti-HEV positive. Among the human populations, Bedouins and non-Bedouin Arabs had a significantly higher prevalence of HEV antibodies (21.6% and 15.0%, respectively) compared with the Jewish population (3.1%). Seropositivity increased significantly with age in all human populations, reaching 47.6% and 34.8% among ≥40 years old, in Bedouins and non-Bedouin Arabs, respectively. The high seropositivity in camels and in ≥40 years old Bedouins and non-Bedouin Arabs suggests that HEV is endemic in Israel. The low HEV seroprevalence in Jews could be attributed to higher socio-economic status.
KW - Arabs (Muslims, non-Bedouins)
KW - Bedouins
KW - Dromedary camels
KW - Hepatitis E
KW - Jews
KW - Seroprevalence
KW - Zoonozis
UR - http://www.scopus.com/inward/record.url?scp=85062881253&partnerID=8YFLogxK
U2 - 10.1017/S0950268819000062
DO - 10.1017/S0950268819000062
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85062881253
SN - 0950-2688
VL - 147
JO - Epidemiology and Infection
JF - Epidemiology and Infection
M1 - e92
ER -